Myostatin is a negative regulator of skeletal muscle growth. Myostatin mutations and
pharmacological strategies increase muscle mass in vivo, suggesting that myostatin …

Myostatin (MSTN) is a muscle-specific secreted peptide that functions to limit muscle growth
through an autocrine regulatory feedback loop. Loss of MSTN activity in cattle, mice, and …

THE PLASTICITY OF SKELETAL muscle continues to fascinate physiologists and cell
biologists. Many of the key molecules in the pathways that signal growth or atrophy of …

Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Background Loss of skeletal muscle mass and function in humans is associated with
significant morbidity and mortality. The role of myostatin as a key negative regulator of …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

Myostatin, or GDF-8 (growth and differentiation factor-8), was first identified through
sequence identity with members of the BMP (bone morphogenetic protein)/TGF-β …